{"id":"tp-39062","type":"article-newspaper","title":"BioNTech to Evaluate Pumitamig With Gilead’s Trodelvy","author":"John Kim","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/business/39062","datePublished":"2026-10-23T14:47:29.000Z","dateModified":"2026-10-23T14:47:29.000Z","language":"en","abstract":"The companies are examining the combination as an initial treatment for triple-negative breast cancer with low or absent PD-L1 expression.","section":"Business","references":[]}